Cytokine release syndrome (CRS) is a systemic inflammatory response with outpouring of the inflammatory cytokines due to stimulus triggered by a variety of factors such as infections, immunotherapy, especially those involving T-cell engagers and certain other drugs. Even though cytokines acts to direct immune response, the higher levels of cytokines with increased inflammation can be harmful as they interfere with a number of body functions. In severe cases, CRS can cause organ failure in heart, lung, kidney, liver, and brain function that may even lead to death.
The main cytokines implicated in the pathogenesis of CRS include interleukin-6 (IL-6), IL-10, tumour necrosis factor (TNF), IL-1, IL-2, IL-8, interferon (IFN)-γ, monocyte chemo attractant protein 1 (MCP-1) and granulocyte-macrophage colony-stimulating factor (GM-CSF) and others. CRS clinically manifests when large numbers of lymphocytes (B cells, T cells, and/or natural killer cells) and/or myeloid cells (macrophages, dendritic cells, and monocytes) become activated and release inflammatory cytokines.
Get FREE sample copy at:
The Cytokine Release Syndrome market report also covers emerging drugs, current treatment practices, Cytokine Release Syndrome market share of the individual therapies, current and forecasted Cytokine Release Syndrome Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Cytokine Release Syndrome treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Cytokine Release Syndrome Market Key Facts
The reported incidence of CRS after CAR T-cell therapy ranges from 50% to 100%, with 13% to 48% of patients experiencing the severe or life-threatening form.(Robert et al.)
It is being observed that children seem to be at a higher risk of developing CRS than adults.
Various studies estimated CRS in several hematologic malignancies, such as acute lymphoblastic B cell leukemia (B-ALL), chronic lymphocytic leukemia (CLL), and diffuse large B cell lymphoma (DLBCL) and myeloma with an estimated range of 70%, 80%, 90% and 50% respectively. (Maude et al., Neelapu et al., Turle et al., Ali et al.,)
Key Benefits of Cytokine Release Syndrome Market Report
Cytokine Release Syndrome market report provides an in-depth analysis of Cytokine Release Syndrome Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Cytokine Release Syndrome market report will help in developing business strategies by understanding the Cytokine Release Syndrome Market trends & developments, key players and future market competition that will shape and drive the Cytokine Release Syndrome market in the upcoming years.
The Cytokine Release Syndrome market report covers Cytokine Release Syndrome current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Cytokine Release Syndrome market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
The Cytokine Release Syndrome market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Cytokine Release Syndrome market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Cytokine Release Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Cytokine Release Syndrome Epidemiology
The Cytokine Release Syndrome epidemiology section covers insights about historical and current Cytokine Release Syndrome patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Cytokine Release Syndrome Drugs Uptake and Key Market Players
The Cytokine Release Syndrome Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cytokine Release Syndrome market or expected to get launched in the market during the study period. The analysis covers Cytokine Release Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Expected launch of emerging therapies shall fuel the growth of the market during the forecast period, i.e., 2019– 2030. The rising usage of CART therapies have prompted the pharmaceutical companies to develop new therapies to prevent and treat CRS in order to provide safe treatment options.
Along with growing experience in the clinical application of potent immunotherapeutic agents, various therapies are emerging to target inherent and potentially fatal adverse effects such as CRS.
Companies all over the globe are persistently working towards the development of new treatment therapies and some of the key players at the global level includes:
Kite, (A Gilead Company)
And many others.
Table of Content
1. Key Insights
2. Executive Summary
3. Cytokine Release Syndrome Competitive Intelligence Analysis
4. Cytokine Release Syndrome Market Overview at a Glance
5. Cytokine Release Syndrome Disease Background and Overview
6. Cytokine Release Syndrome Patient Journey
7. Cytokine Release Syndrome Epidemiology and Patient Population
8. Cytokine Release Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Cytokine Release Syndrome Unmet Needs
10. Key Endpoints of Cytokine Release Syndrome Treatment
11. Cytokine Release Syndrome Marketed Products
12. Cytokine Release Syndrome Emerging Therapies
13. Cytokine Release Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Cytokine Release Syndrome Market Outlook (7 major markets)
16. Cytokine Release Syndrome Access and Reimbursement Overview
17. KOL Views on the Cytokine Release Syndrome Market.
18. Cytokine Release Syndrome Market Drivers
19. Cytokine Release Syndrome Market Barriers
21. DelveInsight Capabilities
Get FREE sample copy at:
DelveInsight’s ‘Cytokine Release Syndrome (CRS) Epidemiology Forecast–2030’ report delivers an in-depth understanding of the Cytokine Release Syndrome (CRS), historical and forecasted epidemiology as well as the Cytokine Release Syndrome trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) and Japan.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States